AMZEEQ
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMZEEQ (AMZEEQ).
Topical antibiotic and anti-inflammatory: inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, and reduces pro-inflammatory cytokine production.
| Metabolism | Minimal systemic absorption; not extensively metabolized. |
| Excretion | Renal: 30% as unchanged drug; Fecal: 70% as metabolites and unchanged drug via biliary excretion. |
| Half-life | Terminal half-life is approximately 28 days due to accumulation in the skin and hair follicles; clinical context: supports once-weekly dosing. |
| Protein binding | 99% bound to plasma proteins, primarily albumin and lipoproteins. |
| Volume of Distribution | Approximately 12 L/kg, indicating extensive distribution into tissues including skin and sebaceous glands. |
| Bioavailability | Topical: Minimal systemic absorption, approximately 1% of applied dose. |
| Onset of Action | Topical: Reduction in acne lesions observed as early as 4 weeks, with maximum effect by 12 weeks. |
| Duration of Action | Prolonged post-treatment effect lasting up to 12 weeks after last application due to dermal reservoir; once-weekly application maintains steady-state. |
Apply a thin layer to affected areas twice daily (morning and evening). Topical, 1.5% w/w.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dosage adjustment required for renal impairment. |
| Liver impairment | No dosage adjustment required for hepatic impairment. |
| Pediatric use | Not recommended for patients under 12 years of age; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment; use same as adults with caution for skin fragility. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMZEEQ (AMZEEQ).
| Breastfeeding | Unknown if excreted in human milk; M/P ratio not available. Use with caution; avoid application to breast area. |
| Teratogenic Risk | Limited human data; animal studies show no teratogenic effects at systemic exposures up to 1.7 times the MRHD. No known fetal risk; avoid first trimester due to theoretical risk from systemic absorption. |
| Fetal Monitoring | Monitor for local skin irritation; no specific fetal monitoring required. |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
["Hypersensitivity to any component of the formulation."]
| Precautions | ["Use may result in overgrowth of nonsusceptible organisms including fungi.","Avoid contact with eyes, mouth, and mucous membranes.","Not for oral, ophthalmic, or intravaginal use."] |
| Food/Dietary | No significant food interactions reported with topical AMZEEQ. However, oral minocycline absorption is affected by dairy products; for topical foam, no dietary restrictions are necessary. |
| Clinical Pearls |
Loading safety data…
| Fertility Effects | No known effect on fertility based on animal studies. |
| AMZEEQ (minocycline) 4% foam is a topical antibiotic indicated for inflammatory lesions of rosacea. Avoid contact with eyes and mucous membranes. Use once daily. May cause skin yellowing (pseudolacte) and hyperpigmentation, especially in dark-skinned patients. Consider sunscreen use due to photosensitivity risk. Not for oral administration. |
| Patient Advice | Apply foam to affected areas of face once daily, avoiding eyes and mouth. · Wash hands after application. · May cause temporary yellowing of skin or fingernails; not harmful. · Use sunscreen and protective clothing to prevent sunburn. · Do not swallow or apply to large skin areas. · Inform doctor if pregnant, breastfeeding, or planning pregnancy. · Avoid using other topical products on treated areas unless directed by doctor. |